ReviewCancers2017
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.
Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy.Cancer cell international · 2026Review
- Application of CAR-T therapy in solid tumors: current opportunities and challenges.Cancer gene therapy · 2026Review
- CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.Frontiers in immunology · 2026Review
- Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions.Journal of the Egyptian National Cancer Institute · 2025Review
- Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer.Science advances · 2024Article
- Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.Experimental hematology & oncology · 2024Review
- Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.Vaccines · 2024Review
- Cancer biotherapy: review and prospect.Clinical and experimental medicine · 2024Review
- Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).International journal of oncology · 2024Review
- Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review).Oncology letters · 2023Review
- Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.Cells · 2023Review
- Visualizing cell-cell communication using synthetic notch activated MRI.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.Biomolecules · 2023Review
- Recent Advances in Cancer Immunotherapy Delivery Modalities.Pharmaceutics · 2023Review
- Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future.Journal of immunotherapy and precision oncology · 2023Review
- Insights in the host response towards biomaterial-based scaffolds for cancer therapy.Frontiers in bioengineering and biotechnology · 2023Review
- CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric Antigen Receptor (CAR) T-cells are T-cells with recombinant receptors targeted to tumor antigens. CAR-T cell therapy has emerged as a mode of immunotherapy and is now being extensively explored in hematologic cancer. In contrast, CAR-T cell use in solid tumors has been hampered by multiple obstacles. Several approaches have been taken to circumvent these obstacles, including the regional delivery of CAR-T cells. Regional CAR-T cell delivery can theoretically compensate for poor T-cell trafficking and tumor antigen specificity while avoiding systemic toxicity associated with intravenous delivery. We reviewed completed clinical trials for the treatment of glioblastoma and metastatic colorectal cancer and examined the data in these studies for safety, efficacy, and potential advantages that regional delivery may confer over systemic delivery. Our appraisal of the available literature revealed that regional delivery of CAR-T cells in both glioblastoma and hepatic colorectal metastases was generally well tolerated and efficacious in select instances. We propose that the regional delivery of CAR-T cells is an area of potential growth in the solid tumor immunotherapy, and look towards future clinical trials in head and neck cancer, mesothelioma, and peritoneal carcinomatosis as the use of this technique expands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.